MedTrace Logo

The Addition of Metformin to Definitive Radiotherapy in Patients With Stage III NSCLC

NCT04170959 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2021-01-15

No results posted yet for this study

Summary

Study the effect of metformin when added to definitive locoregional radiotherapy on locoregional control and relapse rate in stage III non-small cell lung cancer patients receiving sequential chemoradiotherapy. Try to identify subsets of patients who derive maximum benefit of adding metformin to radiotherapy using innovative biomarkers.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Metformin

Metformin 500 mg given 14 days before start until the end of radiation therapy. Once daily during the first 7 days, afterwards twice daily until the end of treatment.

OTHER

No metformin

Standard of care without metformin.

Sponsors & Collaborators

Principal Investigators

  • Jan van Meerbeeck, PhD, MD · P.I.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-30
Primary Completion
2021-01-08
Completion
2021-01-08

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04170959 on ClinicalTrials.gov